Actively Recruiting
A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
Led by Meng Chao Hepatobiliary Hospital of Fujian Medical University · Updated on 2025-05-15
40
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of cadonilimab combined with Regorafenib in patients with hepatocellular carcinoma who failed camrelizumab plus apatinib.
CONDITIONS
Official Title
A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed a written informed consent form before enrollment
- Age over 18 years, any sex
- Histologically or pathologically confirmed intermediate or advanced hepatocellular carcinoma, or cirrhosis patients meeting American Association for the Study of Liver Diseases clinical criteria
- Disease progressed on camrelizumab plus apatinib treatment
- Child-Pugh Class A liver function
- Eastern Cooperative Oncology Group performance status score of 0 to 1
- At least one measurable lesion according to RECIST 1.1
- Expected survival of at least 12 weeks
- Adequate vital organ function with specified blood counts and liver/kidney function limits
- Normal coagulation function without active bleeding or thrombosis
- Non-surgical sterilization or female patients of childbearing potential
- Willingness to voluntarily participate and comply with safety and survival follow-up
You will not qualify if you...
- Presence of fibrolamellar, sarcomatoid hepatocellular carcinoma, or cholangiocarcinoma
- History of hepatic encephalopathy
- History of liver transplantation
- Significant pericardial or pleural effusion requiring drainage
- Clinically apparent ascites detected or requiring drainage
- Simultaneous infection with HBV and HCV (except resolved HCV infection)
- Central nervous system or meningeal metastasis
- Bleeding from esophageal or gastric varices within 6 months before treatment
- Bleeding events grade 3 or higher within 4 weeks before treatment
- Arterial or venous thromboembolic events within 6 months before treatment
- Uncontrolled high blood pressure
- Symptomatic congestive heart failure
- Severe bleeding tendencies or coagulation disorders
- History of gastrointestinal perforation, fistula, or intestinal obstruction within 6 months before treatment
- Active or history of autoimmune disease
- HIV infection
- Other serious illnesses endangering safety or study completion as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mengchao Hepatobiliary Hospital, Fujian Medical University
Fuzhou, Fujian, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here